Sleep Apnea
Sleep apnea is not just a snoring problem. It is a metabolic and cardiovascular disease that manifests during sleep. Repeated airway obstruction produces intermittent hypoxia, sympathetic surges, cortisol spikes, insulin resistance, systemic inflammation, and endothelial dysfunction that accelerate cardiovascular disease, cognitive decline, and metabolic deterioration 24 hours a day. Conventional treatment prescribes CPAP. Functional medicine evaluates and treats the metabolic, hormonal, and inflammatory consequences that CPAP alone does not address.
Condition: Sleep Apnea | Category: Neurological and Metabolic Health | Reviewed by: Brian Lamkin, DO
What Is Sleep Apnea?
Obstructive sleep apnea (OSA) is a condition in which the upper airway repeatedly collapses during sleep, producing episodes of partial (hypopnea) or complete (apnea) airflow cessation lasting 10 seconds or longer. Each episode produces oxygen desaturation (intermittent hypoxia), a sympathetic nervous system surge, a cortisol spike, and a micro-awakening that fragments sleep architecture. The Apnea-Hypopnea Index (AHI) quantifies severity: mild (5 to 14 events/hour), moderate (15 to 29), and severe (30 or more).
An estimated 80 percent of moderate to severe OSA cases remain undiagnosed. The condition is commonly framed as a sleep disorder, but the systemic consequences of intermittent hypoxia operate 24 hours a day. Repeated oxygen desaturation produces oxidative stress, systemic inflammation, endothelial dysfunction, insulin resistance, hypertension, and HPA axis dysregulation. These are not side effects of poor sleep. They are direct pathophysiological consequences of intermittent tissue hypoxia that produce cardiovascular disease, cognitive decline, and metabolic deterioration independently of sleep quality.
Key principle: CPAP treats the airway obstruction. It does not treat the metabolic, inflammatory, hormonal, and cardiovascular consequences that have already developed from years of undiagnosed intermittent hypoxia. Comprehensive sleep apnea management requires both airway management and systematic evaluation and treatment of the systemic damage the condition has produced.
Why Sleep Apnea Matters
Cardiovascular and Metabolic Impact
- Untreated moderate to severe OSA doubles cardiovascular event risk including heart attack, stroke, atrial fibrillation, and heart failure
- OSA is the most common cause of treatment-resistant hypertension: 80 percent of resistant hypertension patients have undiagnosed OSA
- Insulin resistance develops independently of obesity: intermittent hypoxia directly impairs insulin signaling, producing type 2 diabetes risk even in lean patients
- Testosterone suppression: intermittent hypoxia damages Leydig cells and sleep fragmentation disrupts nocturnal testosterone peaks, producing low testosterone that compounds metabolic decline
Why Standard Treatment Is Incomplete
- CPAP addresses the obstruction but not the consequences: insulin resistance, inflammation, endothelial dysfunction, and hormonal suppression from years of untreated OSA require independent treatment
- No metabolic evaluation is performed at diagnosis: fasting insulin, hs-CRP, testosterone, thyroid panel, and cardiovascular risk markers are not part of standard sleep study follow-up
- Weight management is advised generically: the bidirectional relationship between OSA and insulin resistance (each worsening the other) is not addressed with metabolic intervention
- CPAP adherence is poor: approximately 50 percent of patients abandon CPAP within the first year, leaving the underlying condition and its consequences untreated
Common Symptoms
Nocturnal
- Loud snoring with observed apneas
- Gasping or choking during sleep
- Nocturia (frequent nighttime urination)
- Night sweats from sympathetic surges
Daytime
Metabolic Signals
- Treatment-resistant hypertension
- Unexplained weight gain and visceral adiposity
- Worsening blood sugar control
- Low libido and erectile dysfunction
Root Causes: A Functional Medicine Perspective
Sleep apnea involves both structural (airway) and systemic (metabolic) components. The structural obstruction produces the apnea events. The systemic consequences produce the cardiovascular and metabolic disease that is ultimately more dangerous than the airway obstruction itself.
Structural and Anatomical Factors
Upper airway anatomy (retrognathia, macroglossia, large tonsils, deviated septum), pharyngeal fat deposition from visceral adiposity, and pharyngeal muscle hypotonia during sleep create the mechanical obstruction. Hypothyroidism produces tissue edema (myxedema) that narrows the airway and reduces pharyngeal muscle tone, making thyroid evaluation a required component of every OSA assessment.
The Intermittent Hypoxia Cascade
Each apnea event produces oxygen desaturation followed by reoxygenation. This intermittent hypoxia/reoxygenation cycle generates reactive oxygen species (oxidative stress), activates NF-kB inflammatory pathways, damages endothelial nitric oxide production, and triggers sympathetic surges that elevate blood pressure. Over months and years, this produces the same endothelial dysfunction and vascular inflammation that drives atherosclerosis, independent of traditional cardiovascular risk factors.
Metabolic Bidirectional Loop
Insulin resistance and OSA exist in a bidirectional cycle: OSA produces insulin resistance through intermittent hypoxia and sympathetic activation; insulin resistance promotes weight gain and visceral fat accumulation that worsens the airway obstruction; the worsened obstruction produces more hypoxia and more insulin resistance. Breaking this cycle requires metabolic intervention alongside airway management. CPAP alone does not resolve the metabolic component.
Conventional vs Functional Medicine Approach
| Domain | Conventional Medicine | Functional Medicine |
|---|---|---|
| Diagnosis | Polysomnography or home sleep test; AHI classification | Same diagnostic tools plus comprehensive metabolic, hormonal, and cardiovascular evaluation at the time of diagnosis |
| Treatment | CPAP; weight loss advice; oral appliance if mild | CPAP when indicated plus insulin sensitization, anti-inflammatory protocols, thyroid optimization, testosterone evaluation, cardiovascular risk assessment |
| Metabolic | "Lose weight" without metabolic testing | Fasting insulin, HOMA-IR, hs-CRP, lipid panel with TG/HDL ratio to identify and treat the specific metabolic consequences |
| Hormonal | Not evaluated | Testosterone, thyroid panel, cortisol assessed as both consequences and contributors to OSA |
Key Labs to Evaluate
How to Interpret These Labs Together
Elevated fasting insulin with elevated hs-CRP and low free testosterone in a newly diagnosed OSA patient identifies the full metabolic cascade: intermittent hypoxia has produced insulin resistance, systemic inflammation, and testosterone suppression. CPAP will improve oxygen saturation but will not independently reverse the insulin resistance, reduce the inflammation, or restore the testosterone. Each requires targeted intervention alongside airway management.
Treatment-resistant hypertension with elevated HbA1c, elevated triglycerides, and low HDL in a patient with snoring and daytime sleepiness should trigger immediate sleep study referral. This metabolic cluster is the signature of undiagnosed OSA producing cardiovascular and metabolic disease through years of nocturnal hypoxia.
Common Patterns Seen in Patients
- The patient on CPAP for 3 years who still has metabolic syndrome: Diagnosed with moderate OSA (AHI 22). CPAP adherent with normalized AHI on treatment. But fasting insulin 18, HbA1c 5.9, hs-CRP 3.6, testosterone low. The years of intermittent hypoxia before diagnosis produced metabolic damage that CPAP cannot reverse. Insulin sensitization, anti-inflammatory protocols, and testosterone evaluation were never performed at diagnosis or follow-up.
- The low testosterone patient whose OSA was never screened: 48-year-old man with low testosterone, fatigue, weight gain, and erectile dysfunction. Started on testosterone replacement. Symptoms partially improved. Sleep study: AHI 34 (severe OSA). The low testosterone was a consequence of OSA, not an independent condition. Treating the testosterone without treating the cause produces incomplete results and may worsen the OSA through fluid retention.
- The "resistant hypertension" patient taking 3 medications: Blood pressure 148/92 on amlodipine, lisinopril, and hydrochlorothiazide. Loud snoring per spouse. Sleep study: AHI 28 (moderate OSA). 80 percent of resistant hypertension is driven by undiagnosed OSA. CPAP plus metabolic optimization reduced blood pressure to 124/78 and allowed discontinuation of one antihypertensive medication.
Treatment and Optimization Strategy
Airway Management Plus Metabolic Restoration
Airway and Structural
- CPAP therapy: gold standard for moderate to severe OSA. Addresses the mechanical obstruction and normalizes nocturnal oxygen saturation
- Oral appliance therapy: mandibular advancement device for mild to moderate OSA or CPAP-intolerant patients
- Weight optimization: reducing visceral adiposity decreases pharyngeal fat deposition. Even 10 percent weight loss can reduce AHI by 26 to 50 percent
- Thyroid optimization: correcting hypothyroidism reduces tissue edema and improves pharyngeal muscle tone
Metabolic and Systemic
- Insulin sensitization: time-restricted eating, berberine, resistance training to break the OSA-insulin resistance bidirectional cycle
- Anti-inflammatory protocols: omega-3 (3 to 4g EPA+DHA), curcumin for NF-kB inhibition, antioxidant support for oxidative stress from intermittent hypoxia
- Testosterone evaluation: assess whether low testosterone is an OSA consequence (treat OSA first) or a contributing factor (treat both)
- Cardiovascular risk assessment: comprehensive lipid panel, hs-CRP, endothelial function assessment, blood pressure optimization
What Most Doctors Miss
- No metabolic evaluation at OSA diagnosis: fasting insulin, hs-CRP, testosterone, and thyroid are not part of standard sleep study follow-up despite being the most consequential systemic effects of the condition.
- CPAP is necessary but not sufficient: CPAP normalizes the AHI but does not reverse the years of metabolic damage from intermittent hypoxia. Insulin resistance, inflammation, and testosterone suppression require independent evaluation and treatment.
- OSA causes resistant hypertension: 80 percent of treatment-resistant hypertension is driven by undiagnosed OSA. A sleep study should be ordered for every patient requiring 3 or more antihypertensive medications.
- Low testosterone in men may be an OSA consequence: prescribing testosterone replacement without screening for OSA treats the downstream effect while the upstream cause continues to produce damage.
When to Seek Medical Care
If you snore loudly, have witnessed apneas, experience excessive daytime sleepiness, morning headaches, nocturia, treatment-resistant hypertension, unexplained weight gain, low testosterone, or worsening blood sugar control, a sleep evaluation and comprehensive metabolic assessment are warranted. Sleep apnea is one of the most consequential and most commonly undiagnosed conditions in medicine.
Recommended Testing
Sleep apnea evaluation requires both diagnostic sleep testing and comprehensive metabolic assessment to identify the systemic consequences that CPAP alone does not address.
Diagnostic
- Polysomnography or Home Sleep Test
- AHI classification
- Oxygen desaturation index
Metabolic and Hormonal
- Fasting Insulin / HOMA-IR
- HbA1c
- hs-CRP
- Free Testosterone, TSH, Free T3
- Lipid Panel with TG/HDL Ratio
Recommended Panel
Need hormonal and inflammatory testing alongside metabolic markers?
Explore All Testing Options →Frequently Asked Questions
What is sleep apnea?
Sleep apnea is a condition of repeated upper airway collapse during sleep producing intermittent oxygen deprivation. Each episode triggers sympathetic surges, cortisol spikes, and micro-awakenings. Over time, this produces insulin resistance, inflammation, endothelial dysfunction, hypertension, and cardiovascular disease that operate 24 hours a day.
Is CPAP the only treatment?
CPAP is the gold standard for airway management but addresses only the mechanical obstruction. It does not treat the metabolic consequences that have already developed. Comprehensive management includes CPAP alongside insulin sensitization, anti-inflammatory protocols, hormonal evaluation, and cardiovascular risk assessment.
Can sleep apnea cause weight gain?
Yes. OSA produces insulin resistance, elevated cortisol, leptin resistance, and growth hormone suppression, all of which promote weight gain. The increased weight then worsens the airway obstruction. Breaking this bidirectional cycle requires metabolic intervention alongside CPAP.
Does sleep apnea affect testosterone?
Yes. Intermittent hypoxia damages Leydig cells. Sleep fragmentation disrupts nocturnal testosterone production peaks. Elevated cortisol from sympathetic surges suppresses the HPG axis. Many men with low testosterone have undiagnosed OSA as a contributing or primary cause.
Is sleep apnea connected to heart disease?
Yes. OSA is an independent cardiovascular risk factor. Intermittent hypoxia produces oxidative stress and endothelial dysfunction. Sympathetic surges produce hypertension. Insulin resistance accelerates atherosclerosis. Untreated moderate to severe OSA doubles cardiovascular event risk.
How The Lamkin Clinic Approaches Sleep Apnea
Sleep apnea is not a sleep problem. It is a cardiovascular and metabolic disease that happens to manifest during sleep. When I diagnose OSA, I do not just prescribe CPAP and send the patient home. I draw labs. Fasting insulin, hs-CRP, testosterone, thyroid, and a full lipid panel. Because every one of those systems has been damaged by years of intermittent hypoxia, and CPAP alone does not repair that damage. CPAP keeps the airway open. I treat everything that happened while the airway was closed.
Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma
At The Lamkin Clinic, sleep apnea management goes beyond CPAP. Every OSA diagnosis includes comprehensive metabolic and hormonal evaluation to identify the systemic consequences of intermittent hypoxia: insulin resistance, systemic inflammation, testosterone suppression, thyroid dysfunction, and cardiovascular risk. Treatment targets both the airway obstruction and the metabolic damage it has produced, because reversing the consequences is as important as preventing new episodes.
Related Conditions
Related Symptoms
Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.
Sleep apnea is a cardiovascular and metabolic disease. CPAP alone is not sufficient treatment.
The Lamkin Clinic evaluates every OSA diagnosis with comprehensive metabolic, hormonal, and cardiovascular assessment alongside airway management. Schedule a consultation.
Schedule a ConsultationMedical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.
